PHIO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PHIO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Phio Pharmaceuticals's yield on cost for the quarter that ended in Dec. 2024 was 0.00.
The historical rank and industry rank for Phio Pharmaceuticals's 5-Year Yield-on-Cost % or its related term are showing as below:
For the Biotechnology subindustry, Phio Pharmaceuticals's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Phio Pharmaceuticals's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Phio Pharmaceuticals's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Phio Pharmaceuticals is calculated as
Yield-on-Cost | = | Dividend Yield % | * | (1 | + | Dividend Growth Rate)^5 |
Phio Pharmaceuticals (NAS:PHIO) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Thank you for viewing the detailed overview of Phio Pharmaceuticals's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.
Robert J Bitterman | director | C/O RXI PHARMACEUTICALS CORPORATION, 1500 WEST PARK DRIVE, SUITE 210, WESTBOROUGH MA 01581 |
Robert L Ferrara | director | 257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752 |
Patricia A Bradford | director | UNISYS CORPORATION, 801 LAKEVIEW DRIVE, SUITE 100, BLUE BELL PA 19422 |
Gerrit Dispersyn | officer: Chief Development Officer | 257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752 |
John A Barrett | officer: Chief Development Officer | 257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752 |
Geert Cauwenbergh | director, officer: President and CEO | 1 STULTS DRIVE, PLAINSBORO NJ 08536 |
Alexey Eliseev | officer: Chief Business Officer | 257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752 |
Jonathan E Freeman | director | 257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752 |
Curtis Lockshin | director | 4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137 |
H. Paul Dorman | director | 1500 WEST PARK DRIVE, SUITE 210, WESTBOROUGH MA 01581 |
Opko Health, Inc. | 10 percent owner | 4400 BISCAYNE BLVD., MIAMI FL 33137 |
Advanced Rna Technologies, Llc | 10 percent owner | 1 KENDALL SQUARE BUILDING 200, SUITE 2203, CAMBRIDGE MA 02139 |
Keith L Brownlie | director | 777 OLD SAW MILL RIVER RD, TARRYTOWN NY 10591 |
Pamela Pavco | officer: Chief Development Officer | C/O RXI PHARMACEUTICALS CORPORATION, 1500 WEST PARK DRIVE, WESTBOROUGH MA 01581 |
Caitlin Kontulis | officer: Secretary and Controller | 1500 WEST PARK DRIVE, SUITE 210, WESTBOROUGH MA 01581 |
From GuruFocus
By Marketwired • 08-21-2023
By Marketwired • 09-06-2023
By PRNewswire PRNewswire • 04-17-2023
By PRNewswire PRNewswire • 02-22-2023
By PRNewswire PRNewswire • 05-24-2023
By Marketwired • 10-11-2023
By PRNewswire PRNewswire • 05-18-2023
By PRNewswire PRNewswire • 04-20-2023
By Marketwired • 05-17-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.